Novo Holdings announces 2025 Annual Results Novo Holdings announced its financial results for 2025. Despite a challenging global environment, Novo Holdings has made significant progress on its Strategy 2030 during 2025 and delivered on its priorities. The Novo Holdings Investment Portfolio continued to perform well on both an absolute and relative basis, with a return […]
PDUFA action date for Hansa Biopharma’s imlifidase BLA set for December 19, 2026 Hansa Biopharma announced that the Food and Drug Administration (FDA) has notified the company that the previously accepted Biologics License Application (BLA) for imlifidase has been assigned a Prescription Drug User Fee Act (PDUFA) action date of December 19, 2026. 📺Optimum TV […]
As one of the organisers, Optimum is proud to partner with Anglonordic year on year to curate an awesome agenda for this fantastic event. Exclusively for European investors and R&D companies…
JPM 2026 was touted as the event that would usher in the best year in biotech in a long time. But when it happened there was a distinct lack of mega-deals to shout about. The elephant, you might say, was not in the room. Does this bode ill for 2026? Or is news of such […]
What an incredible few days at Jefferies & London Life Science Week! 🎉 A huge thank you to Jefferies, the BioIndustry Association (BIA), MedCity, and London & Partners for hosting this goliath event. It gets bigger, better and more impactful every year, and we’re proud to be part of it. We are glad so many […]
